130 related articles for article (PubMed ID: 33523597)
1. ADR databases for on-site clinical use: Potentials of summary of products characteristics.
Eiermann B; Rodriguez D; Cohen P; Gustafsson LL
Basic Clin Pharmacol Toxicol; 2021 Apr; 128(4):557-567. PubMed ID: 33523597
[TBL] [Abstract][Full Text] [Related]
2. An Adverse Drug Reaction Database for Clinical Use - Potential of and Difficulties with the Summary of Product Characteristics.
Eiermann B; Rodrigues D; Cohen P; Gustafsson LL
Stud Health Technol Inform; 2022 May; 294():450-454. PubMed ID: 35612120
[TBL] [Abstract][Full Text] [Related]
3. Information on adverse drug reactions-Proof of principle for a structured database that allows customization of drug information.
Kusch MKP; Zien A; Hachenberg C; Haefeli WE; Seidling HM
Int J Med Inform; 2020 Jan; 133():103970. PubMed ID: 31704490
[TBL] [Abstract][Full Text] [Related]
4. E-pharmacovigilance: development and implementation of a computable knowledge base to identify adverse drug reactions.
Neubert A; Dormann H; Prokosch HU; Bürkle T; Rascher W; Sojer R; Brune K; Criegee-Rieck M
Br J Clin Pharmacol; 2013 Sep; 76 Suppl 1(Suppl 1):69-77. PubMed ID: 23586589
[TBL] [Abstract][Full Text] [Related]
5. Variation in adverse drug reactions listed in product information for antidepressants and anticonvulsants, between the USA and Europe: a comparison review of paired regulatory documents.
Cornelius VR; Liu K; Peacock J; Sauzet O
BMJ Open; 2016 Mar; 6(3):e010599. PubMed ID: 26996819
[TBL] [Abstract][Full Text] [Related]
6. Effect of safety issues with HIV drugs on the approval process of other drugs in the same class: an analysis of European Public Assessment Reports.
Arnardottir AH; Haaijer-Ruskamp FM; Straus SM; de Graeff PA; Mol PG
Drug Saf; 2011 Nov; 34(11):1101-14. PubMed ID: 21981437
[TBL] [Abstract][Full Text] [Related]
7. Regulatory Safety Learning Driven by the Mechanism of Action: The Case of TNF-α Inhibitors.
Minnema LA; Giezen TJ; Hoekman J; Egberts TCG; Leufkens HGM; Gardarsdottir H
Clin Pharmacol Ther; 2021 Jul; 110(1):123-131. PubMed ID: 33278830
[TBL] [Abstract][Full Text] [Related]
8. Ontological Organization and Bioinformatic Analysis of Adverse Drug Reactions From Package Inserts: Development and Usability Study.
Li X; Lin X; Ren H; Guo J
J Med Internet Res; 2020 Jul; 22(7):e20443. PubMed ID: 32706718
[TBL] [Abstract][Full Text] [Related]
9. Supervised signal detection for adverse drug reactions in medication dispensing data.
Hoang T; Liu J; Roughead E; Pratt N; Li J
Comput Methods Programs Biomed; 2018 Jul; 161():25-38. PubMed ID: 29852965
[TBL] [Abstract][Full Text] [Related]
10. Study of serious adverse drug reactions using FDA-approved drug labeling and MedDRA.
Wu L; Ingle T; Liu Z; Zhao-Wong A; Harris S; Thakkar S; Zhou G; Yang J; Xu J; Mehta D; Ge W; Tong W; Fang H
BMC Bioinformatics; 2019 Mar; 20(Suppl 2):97. PubMed ID: 30871458
[TBL] [Abstract][Full Text] [Related]
11. The contribution of Ghanaian patients to the reporting of adverse drug reactions: a quantitative and qualitative study.
Jacobs TG; Hilda Ampadu H; Hoekman J; Dodoo ANO; Mantel-Teeuwisse AK
BMC Public Health; 2018 Dec; 18(1):1384. PubMed ID: 30563498
[TBL] [Abstract][Full Text] [Related]
12. Adverse Drug Reactions from Real-World Data in Inflammatory Bowel Disease Patients in the IBDREAM Registry.
Giraud EL; Thomas PWA; van Lint JA; van Puijenbroek EP; Römkens TEH; West RL; Russel MGVM; Jansen JM; Jessurun NT; Hoentjen F;
Drug Saf; 2021 May; 44(5):581-588. PubMed ID: 33538994
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Three Different Data Sources of Adverse Drug Reactions Using Adverse Drug Reaction Data of Fluorouracil for Gastric Cancer as an Example.
Niu R; Chen Y; Xiang Y; Liu Y; Guo J; Feng B
Biol Pharm Bull; 2020; 43(10):1476-1480. PubMed ID: 32999157
[TBL] [Abstract][Full Text] [Related]
14. Knowledge creation about ADRs--turning the perspective from the rear mirror to the projector?
Aagaard L; Soendergaard B; Stenver DI; Hansen EH
Br J Clin Pharmacol; 2008 Mar; 65(3):364-76. PubMed ID: 17961195
[TBL] [Abstract][Full Text] [Related]
15. Complementing the US Food and Drug Administration Adverse Event Reporting System With Adverse Drug Reaction Reporting From Social Media: Comparative Analysis.
Zhou Z; Hultgren KE
JMIR Public Health Surveill; 2020 Sep; 6(3):e19266. PubMed ID: 32996889
[TBL] [Abstract][Full Text] [Related]
16. Impact of information letters on the reporting rate of adverse drug reactions and the quality of the reports: a randomized controlled study.
Johansson ML; Hägg S; Wallerstedt SM
BMC Clin Pharmacol; 2011 Sep; 11():14. PubMed ID: 21899766
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
[TBL] [Abstract][Full Text] [Related]
18. Patient Reporting of Adverse Drug Reactions (ADRs): Survey of Public Awareness and Predictors of Confidence to Report.
Hariraj V; Aziz Z
Ther Innov Regul Sci; 2018 Nov; 52(6):757-763. PubMed ID: 29714567
[TBL] [Abstract][Full Text] [Related]
19. A comprehensive intervention for adverse drug reactions identification and reporting in a Pediatric Emergency Department.
Morales Ríos O; Jasso Gutiérrez L; Talavera JO; Téllez-Rojo MM; Olivar López V; Garduño Espinosa J; Muñoz Hernández O
Int J Clin Pharm; 2016 Feb; 38(1):80-7. PubMed ID: 26499501
[TBL] [Abstract][Full Text] [Related]
20. A dataset of 200 structured product labels annotated for adverse drug reactions.
Demner-Fushman D; Shooshan SE; Rodriguez L; Aronson AR; Lang F; Rogers W; Roberts K; Tonning J
Sci Data; 2018 Jan; 5():180001. PubMed ID: 29381145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
